WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH NEWS

Warptech News aggrega le notizie più rilevanti da oltre 150 fonti internazionali, con classificazione AI e timeline cluster su singole storie.

Navigazione

Home
Archivio
Cerca
Il tuo account

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

How the UK fell out with big pharma — Warptech News

How the UK fell out with big pharma

The U.K. is in the midst of a falling out with big pharma over drug pricing. Merck has walked away from a £1 billion facility in London and pulled its research activities altogether. Now Eli Lilly, Sanofi and AstraZeneca are all rethinking their investments in the country. CNBC's Ritika Gupta discusses with Jimmy Muchechetere, global healthcare & industrials equity research analyst at Investec.

lunedì 15 settembre 2025 New tab

14 words~1 min read

Get this delivered to your inbox, and more info about our products and services.

Related reading

Pharma firms pile pressure on the UK as Trump's drug pricing order looms

A number of global pharma firms have pulled or paused U.K. investment plans amid waning government support and drug pricing talks.

cnbc.com·8 mesi fa

UK has gone from a leader to a laggard in biopharma, Eli Lilly CEO says

Eli Lilly Chief Executive Officer Dave Ricks says a pullback in U.K. biopharmaceutical investments should send a message to U.S.…

cnbc.com·8 mesi fa

telegraph.co.uk

US drugmaker scraps plans for £1bn UK research centre

Merck criticises ‘successive UK governments’ as it cancels King’s Cross development

telegraph.co.uk·8 mesi fa

theguardian.com

Big pharma is at war with the UK, and the government can’t back down now | Nick…

The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of Britain, says…

theguardian.com·7 mesi fa

telegraph.co.uk

NHS pricing row has made Britain unattractive, says drugs giant

The UK’s uncompetitive policies have led to years of chronic underinvestment

telegraph.co.uk·8 mesi fa

theguardian.com

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

theguardian.com·7 mesi fa

Other newsrooms on this story

· 6 sources

Full timeline →

telegraph.co.uk·Sep 10, 2025 · 8 mesi fa
US drugmaker scraps plans for £1bn UK research centre
bbc.com·Sep 11, 2025 · 8 mesi fa
Merck scraps £1bn expansion in the UK over lack of state investment

telegraph.co.uk·Sep 12, 2025 · 8 mesi fa

AstraZeneca pauses £200m Cambridge expansion amid NHS pricing row

theguardian.com·Sep 16, 2025 · 8 mesi fa

Big pharma firms have paused nearly £2bn in UK investments this year

bbc.com·Sep 12, 2025 · 8 mesi fa

AstraZeneca pauses £200m Cambridge investment

theguardian.com·Sep 12, 2025 · 8 mesi fa

Britain is ‘a terrible place’ to sell medicines, says drug firm executive